Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience

Daniel Orbach, Véronique Mosseri, Daniel Pissaloux, Gaelle Pierron, Bernadette Brennan, Andrea Ferrari, Frederic Chibon, Gianni Bisogno, Gian Luca De Salvo, Camille Chakiba, Nadège Corradini, Véronique Minard-Colin, Anna Kelsey, Dominique Ranchère-Vince

Research output: Contribution to journalArticle

Abstract

A genomic index (GI) tool using array comparative genomic hybridization (aCGH) on tumor cells has emerged as independent prognostic factor associated with the risk of metastatic relapse in synovial sarcoma (SS). The aim was to assess GI in pediatric patients with SS, to determine its value as a prognostic factor. All pediatric/adolescent/young adults' (<25 years) with localized SS prospectively included in the European EpSSG-NRSTS05 protocol with a contributive aCGH were selected. Definition of GI was A2 /C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes on aCGH results. GI1 group corresponds to cases with no copy number alterations (flat profile, GI = 0) and GI2 group cases with at least one or more copy number alterations (rearranged profile; GI ≥ 1). Samples were available from 61 patients. The median age of the cohort was 13 years (range: 4-24). Overall, 55.7% were GI1 group, and 44.3% GI2 . After a median follow-up of 62 months (range: 0.1-112), 10 tumor events occurred and five patients died. Respectively, for GI1 versus GI2 groups, five-year event-free survival (EFS) was 93.8 ± 4.2% versus 64.9 ± 10.1% (P < 0.006) and five-year Metastatic-Free Survival (MFS) 93.8 ± 4.2% versus 72.9 ± 9.5% (P < 0.04). In multivariate analysis, GI status as adjusted for IRS group, patient age, site, and tumor size remain independent prognostic for EFS with a relative risk (RR) of 6.4 [1.3-31.9] (P < 0.01) and RR for MFS is 4.8 [0.9-25.7] (P < 0.05). Genomic complexity evaluated through GI may explain the metastatic behavior of pediatric SS.

Original languageEnglish
Pages (from-to)1384-1393
Number of pages10
JournalCancer Medicine
Volume7
Issue number4
DOIs
Publication statusPublished - Apr 2018

Fingerprint

Synovial Sarcoma
Sarcoma
Comparative Genomic Hybridization
Pediatrics
Disease-Free Survival
Neoplasms
Survival
varespladib methyl
Young Adult
Multivariate Analysis
Age Groups
Chromosomes
Recurrence

Cite this

Genomic complexity in pediatric synovial sarcomas (Synobio study) : the European pediatric soft tissue sarcoma group (EpSSG) experience. / Orbach, Daniel; Mosseri, Véronique; Pissaloux, Daniel; Pierron, Gaelle; Brennan, Bernadette; Ferrari, Andrea; Chibon, Frederic; Bisogno, Gianni; De Salvo, Gian Luca; Chakiba, Camille; Corradini, Nadège; Minard-Colin, Véronique; Kelsey, Anna; Ranchère-Vince, Dominique.

In: Cancer Medicine, Vol. 7, No. 4, 04.2018, p. 1384-1393.

Research output: Contribution to journalArticle

Orbach, D, Mosseri, V, Pissaloux, D, Pierron, G, Brennan, B, Ferrari, A, Chibon, F, Bisogno, G, De Salvo, GL, Chakiba, C, Corradini, N, Minard-Colin, V, Kelsey, A & Ranchère-Vince, D 2018, 'Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience', Cancer Medicine, vol. 7, no. 4, pp. 1384-1393. https://doi.org/10.1002/cam4.1415
Orbach, Daniel ; Mosseri, Véronique ; Pissaloux, Daniel ; Pierron, Gaelle ; Brennan, Bernadette ; Ferrari, Andrea ; Chibon, Frederic ; Bisogno, Gianni ; De Salvo, Gian Luca ; Chakiba, Camille ; Corradini, Nadège ; Minard-Colin, Véronique ; Kelsey, Anna ; Ranchère-Vince, Dominique. / Genomic complexity in pediatric synovial sarcomas (Synobio study) : the European pediatric soft tissue sarcoma group (EpSSG) experience. In: Cancer Medicine. 2018 ; Vol. 7, No. 4. pp. 1384-1393.
@article{8d1efb00dd204e459f5678a1b3369768,
title = "Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience",
abstract = "A genomic index (GI) tool using array comparative genomic hybridization (aCGH) on tumor cells has emerged as independent prognostic factor associated with the risk of metastatic relapse in synovial sarcoma (SS). The aim was to assess GI in pediatric patients with SS, to determine its value as a prognostic factor. All pediatric/adolescent/young adults' (<25 years) with localized SS prospectively included in the European EpSSG-NRSTS05 protocol with a contributive aCGH were selected. Definition of GI was A2 /C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes on aCGH results. GI1 group corresponds to cases with no copy number alterations (flat profile, GI = 0) and GI2 group cases with at least one or more copy number alterations (rearranged profile; GI ≥ 1). Samples were available from 61 patients. The median age of the cohort was 13 years (range: 4-24). Overall, 55.7{\%} were GI1 group, and 44.3{\%} GI2 . After a median follow-up of 62 months (range: 0.1-112), 10 tumor events occurred and five patients died. Respectively, for GI1 versus GI2 groups, five-year event-free survival (EFS) was 93.8 ± 4.2{\%} versus 64.9 ± 10.1{\%} (P < 0.006) and five-year Metastatic-Free Survival (MFS) 93.8 ± 4.2{\%} versus 72.9 ± 9.5{\%} (P < 0.04). In multivariate analysis, GI status as adjusted for IRS group, patient age, site, and tumor size remain independent prognostic for EFS with a relative risk (RR) of 6.4 [1.3-31.9] (P < 0.01) and RR for MFS is 4.8 [0.9-25.7] (P < 0.05). Genomic complexity evaluated through GI may explain the metastatic behavior of pediatric SS.",
author = "Daniel Orbach and V{\'e}ronique Mosseri and Daniel Pissaloux and Gaelle Pierron and Bernadette Brennan and Andrea Ferrari and Frederic Chibon and Gianni Bisogno and {De Salvo}, {Gian Luca} and Camille Chakiba and Nad{\`e}ge Corradini and V{\'e}ronique Minard-Colin and Anna Kelsey and Dominique Ranch{\`e}re-Vince",
note = "{\circledC} 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2018",
month = "4",
doi = "10.1002/cam4.1415",
language = "English",
volume = "7",
pages = "1384--1393",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Genomic complexity in pediatric synovial sarcomas (Synobio study)

T2 - the European pediatric soft tissue sarcoma group (EpSSG) experience

AU - Orbach, Daniel

AU - Mosseri, Véronique

AU - Pissaloux, Daniel

AU - Pierron, Gaelle

AU - Brennan, Bernadette

AU - Ferrari, Andrea

AU - Chibon, Frederic

AU - Bisogno, Gianni

AU - De Salvo, Gian Luca

AU - Chakiba, Camille

AU - Corradini, Nadège

AU - Minard-Colin, Véronique

AU - Kelsey, Anna

AU - Ranchère-Vince, Dominique

N1 - © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2018/4

Y1 - 2018/4

N2 - A genomic index (GI) tool using array comparative genomic hybridization (aCGH) on tumor cells has emerged as independent prognostic factor associated with the risk of metastatic relapse in synovial sarcoma (SS). The aim was to assess GI in pediatric patients with SS, to determine its value as a prognostic factor. All pediatric/adolescent/young adults' (<25 years) with localized SS prospectively included in the European EpSSG-NRSTS05 protocol with a contributive aCGH were selected. Definition of GI was A2 /C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes on aCGH results. GI1 group corresponds to cases with no copy number alterations (flat profile, GI = 0) and GI2 group cases with at least one or more copy number alterations (rearranged profile; GI ≥ 1). Samples were available from 61 patients. The median age of the cohort was 13 years (range: 4-24). Overall, 55.7% were GI1 group, and 44.3% GI2 . After a median follow-up of 62 months (range: 0.1-112), 10 tumor events occurred and five patients died. Respectively, for GI1 versus GI2 groups, five-year event-free survival (EFS) was 93.8 ± 4.2% versus 64.9 ± 10.1% (P < 0.006) and five-year Metastatic-Free Survival (MFS) 93.8 ± 4.2% versus 72.9 ± 9.5% (P < 0.04). In multivariate analysis, GI status as adjusted for IRS group, patient age, site, and tumor size remain independent prognostic for EFS with a relative risk (RR) of 6.4 [1.3-31.9] (P < 0.01) and RR for MFS is 4.8 [0.9-25.7] (P < 0.05). Genomic complexity evaluated through GI may explain the metastatic behavior of pediatric SS.

AB - A genomic index (GI) tool using array comparative genomic hybridization (aCGH) on tumor cells has emerged as independent prognostic factor associated with the risk of metastatic relapse in synovial sarcoma (SS). The aim was to assess GI in pediatric patients with SS, to determine its value as a prognostic factor. All pediatric/adolescent/young adults' (<25 years) with localized SS prospectively included in the European EpSSG-NRSTS05 protocol with a contributive aCGH were selected. Definition of GI was A2 /C, where A is the total number of alterations (segmental gains and losses) and C is the number of involved chromosomes on aCGH results. GI1 group corresponds to cases with no copy number alterations (flat profile, GI = 0) and GI2 group cases with at least one or more copy number alterations (rearranged profile; GI ≥ 1). Samples were available from 61 patients. The median age of the cohort was 13 years (range: 4-24). Overall, 55.7% were GI1 group, and 44.3% GI2 . After a median follow-up of 62 months (range: 0.1-112), 10 tumor events occurred and five patients died. Respectively, for GI1 versus GI2 groups, five-year event-free survival (EFS) was 93.8 ± 4.2% versus 64.9 ± 10.1% (P < 0.006) and five-year Metastatic-Free Survival (MFS) 93.8 ± 4.2% versus 72.9 ± 9.5% (P < 0.04). In multivariate analysis, GI status as adjusted for IRS group, patient age, site, and tumor size remain independent prognostic for EFS with a relative risk (RR) of 6.4 [1.3-31.9] (P < 0.01) and RR for MFS is 4.8 [0.9-25.7] (P < 0.05). Genomic complexity evaluated through GI may explain the metastatic behavior of pediatric SS.

U2 - 10.1002/cam4.1415

DO - 10.1002/cam4.1415

M3 - Article

C2 - 29533008

VL - 7

SP - 1384

EP - 1393

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 4

ER -